•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Nantes, France, April 23, 2026 (7:30am CEST) — OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announced that topline results from the TEDOVA Phase 2 international clinical trial of Tedopi® have been selected for an oral presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois, scheduled for May 29 to June 2, 2026.
The presentation will be delivered by Alexandra Leary, MD, PhD, Deputy Head of the Department of Medical Oncology at Gustave Roussy (Paris, France). Dr. Leary, who specializes in gynecological cancers, chairs the GINECO group and serves as Lead Investigator of the TEDOVA Phase 2 trial of Tedopi®.
The TEDOVA trial evaluates Tedopi® as a maintenance treatment for ovarian cancer. The oral abstract is titled: “The neo-epitope-based vaccine OSE-2101 with or without pembrolizumab versus best supportive care as maintenance in platinum-sensitive recurrent ovarian cancer patients with controlled disease after platinum-based chemotherapy: The academic randomized TEDOVA/GINECO-OV244b/ENGOT-ov58 trial”.
Rapid Oral Abstract details: Session: Gynecologic Cancer – Subtrack: Ovarian Cancer; Abstract 5510; Room E450; May 30, 2026, 8:06–8:12am CDT (3:06–3:12pm EST).
TEDOVA is a three-arm Phase 2 study assessing Tedopi® as maintenance therapy, administered alone or in combination with the anti-PD1 immune checkpoint inhibitor Keytruda® (pembrolizumab), versus best supportive care.
The trial includes 185 patients with platinum-sensitive recurrent ovarian cancer who have controlled disease following platinum-based chemotherapy. All participants had already received both bevacizumab and a PARP (Poly ADP-Ribose Polymerase) inhibitor.
The primary endpoint is Progression Free Survival (PFS) for maintenance treatment with Tedopi®, including with a PD1 inhibitor, following platinum-based chemotherapy in relapsed ovarian cancer. The trial is registered as NCT04713514.
OSE Immunotherapeutics is a clinical-stage biotech company focused on developing first-in-class assets in immuno-oncology and immuno-inflammation. The company is based between Nantes and Paris and is listed on Euronext.
ARCAGY-GINECO is a cooperative group founded in 1993 and accredited by the French National Cancer Institute (INCa). It focuses on clinical and translational research in women’s cancers, including gynecologic cancers and metastatic breast cancer.
ENGOT (European Network for Gynecological Oncological Trial groups) is a research network of the European Society of Gynecological Oncology (ESGO), founded in 2007. ENGOT includes 21 cooperative groups from 33 European countries.
Forward-looking statements: The company notes that the press release contains express or implied forward-looking information and statements that are not historical facts, and that actual results may differ materially due to risks and uncertainties.
Premium gym chains are entering a “golden era” that is ending or already in decline, as rising operating costs collide with shifting consumer preferences toward more flexible, community-based ways to exercise. Long-term memberships are shrinking, margins are pressured by higher rents and facility expenses, and competition from smaller, more personalized…
